The NKX2-3 protein was found to be located in the nucleus of tumor cells and was classified as a promising biomarker to predict the response of cancer patients undergoing FOLFOX4 chemotherapy (Li et al., 2012). The gene discussed is NKX2-3; the disease is cancer.